Sex- and Gender-specific Risk Factors of Post-COVID-19 Syndrome: A Population-based Cohort Study in Switzerland

Caroline E. Gebhard, MD^{1*}, Claudia Sütsch, MD^{2,3*}, Susan Bengs, PhD^{2,3}, Manja Deforth, MSc⁴, Karl Philipp Buehler, MD⁵, Nadia Hamouda, MD^{2,3}, Alexander Meisel, MD^{2,3}, Reto A. Schuepbach, MD⁵, Annelies S. Zinkernagel, MD, PhD⁶, Silvio D. Brugger, MD, PhD⁶, Claudio Acevedo, MD⁶, Dimitri Patriki, MD⁷, Benedikt Wiggli, MD⁷, Jürg H. Beer, MD⁷, Andrée Friedl, MD⁷, Raphael Twerenbold, MD⁸, Gabriela M. Kuster, MD^{8,9}, Hans Pargger, MD¹, Sarah Tschudin-Sutter, MD, MSc¹⁰, Joerg C. Schefold, MD¹¹, Thibaud Spinetti, PhD¹¹, Arnaud Dussault-Cloutier^{2,3}, Chiara Henze^{2,3}, Mina Pasqualini^{2,3}, Dominik F. Sager, MSc^{2,3}, Lilian Mayrhofer, MSc¹, Mirjam Grieder, MSc¹, Janna Tontsch, MD¹, Fabian Franzeck, MD^{10,12}, Pedro D. Wendel Garcia, MSc⁵, Daniel A. Hofmaenner, MD⁵, Thomas Scheier, MD⁶, Jan Bartussek, PhD^{5,13}, Leon Chrobok¹, David Stähli¹, Nicola Lott, PhD^{2,3}, Ahmed Haider, PhD^{2,3,14}, Muriel Grämer, PhD^{2,3}, Nidaa Mikail, MD^{2,3}, Alexia Rossi, MD, PhD^{2,3}, Nuria Zellweger¹, Petra Opic, MD, PhD¹, Angela Portmann, MSc^{2,3}, Atanas Todorov, MD, PhD^{2,3}, Aju P. Pazhenkottil, MD², Michael Messerli, MD², Ronny R. Buechel, MD², Philipp A. Kaufmann, MD², Valerie Treyer, PhD², Martin Siegemund, MD¹, Ulrike Held, PhD⁴, Vera Regitz-Zagrosek, MD^{15,16}, Catherine Gebhard, MD, PhD^{2,3,7,17}

¹Intensive Care Unit, University Hospital Basel, Basel, Switzerland

²Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland

³Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland

⁴Department of Biostatistics at Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

⁵Institute of Intensive Care, University Hospital Zurich, University of Zurich, Zurich, Switzerland

⁶Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

⁷Department of Internal Medicine, Cantonal Hospital of Baden, Baden, Switzerland

⁸Department of Cardiology, University Hospital Basel, Basel, Switzerland

⁹Department of Biomedicine, University of Basel, Basel, Switzerland

¹⁰Department of Infectious Diseases and Hospital Epidemiology, University of Basel, Basel, Switzerland

¹¹Department of Intensive Care Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland

¹²Department of Informatics, University Hospital of Basel, Basel, Switzerland

¹³Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland

¹⁴Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, and Department of Radiology, Harvard Medical School, Boston, Massachusetts, United States

¹⁵Charité, Universitätsmedizin Berlin, Germany

¹⁶University of Zurich, Zurich, Switzerland

¹⁷Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria

*These authors contributed equally.

Short title: Sex, Gender, and Post-COVID-19 Syndrome

Abstract: 285

Total word count: 3544

References: 30

Address for correspondence:

Prof. Catherine Gebhard, MD, PhD
Center for Molecular Cardiology, University of Zurich
Department of Nuclear Medicine, University Hospital Zurich
Raemistrasse 100, 8091 Zurich, Switzerland

Tel.: +41 44 255 8919, Fax: +41 44 255 4428

Email: Catherine.gebhard@usz.ch

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background: Evidence to date indicates that mortality of acute coronavirus disease (COVID-19) is higher in men than in women. Conversely, women seem more likely to suffer from long-term consequences of the disease and pronounced negative social and economic impacts. Sex- and gender specific risk factors of COVID-19-related long-term effects are unknown.

Methods: We conducted a multicentre prospective observational cohort study of 5838 (44.6% women) individuals in Switzerland who were tested positive for SARS-CoV-2 RNA between February and December 2020. Of all surviving individuals who met the inclusion criteria, 2799 (1285 [45.9%] women) completed a follow-up questionnaire.

Findings: After a mean follow-up time of 197 ± 77 days, women more often reported at least one persistent symptom (43.0% vs 31.5%, $p < 0.001$) with reduced exercise tolerance and reduced resilience being the most frequently reported symptom in both sexes. Critical illness (intermediate or intensive care unit admission) during acute SARS-CoV-2 infection (odds ratio[95%CI]: 4.00[2.66-6.02], $p < 0.0001$) was a risk factor of post-COVID syndrome in both women and men. Women with pre-existing mental illness (1.81[1.00-3.26], $p = 0.049$), cardiovascular risk factors (1.39[1.03-1.89], $p = 0.033$), higher self-reported domestic stress levels (1.15[1.08-1.22], $p < 0.0001$), and feminine gender identity (1.12[1.02-1.24], $p = 0.02$) increased the odds of experiencing post-COVID syndrome. Conversely, obesity (1.44[1.03-2.02], $p = 0.034$) increased the odds of post-COVID syndrome in men, but not in women. Being responsible for household work (men, OR 0.82[0.69-0.97], $p = 0.021$), taking care of children/relatives (women, 0.90[0.84-0.96], $p = 0.002$) or being pregnant at the time of acute COVID-19 illness (OR 0.48[0.23-1.01], $p = 0.054$) was associated with lower odds of post-COVID syndrome.

Interpretation: Predictors of post-COVID syndrome differ between men and women. Our data reinforce the importance to include sex and gender to identify patients at risk for post-COVID syndrome so that access to care and early intervention can be tailored to their different needs.

Research in context

Evidence before this study: We performed a PubMed search for studies investigating short- and long-term health sequelae in COVID-19 survivors. We included all studies published prior to May 30th, 2021. The search comprised the following terms: (COVID-19 OR SARS-CoV-2 OR Coronavirus disease 2019 OR 2019-nCoV) AND (post COVID OR long COVID OR survivor OR recover OR persistent OR follow up OR discharge OR long-term OR sequelae). Previous studies have reported a variety of symptoms in COVID-19 survivors from different countries such as China (Wuhan), the UK, and the U.S. Overall, these studies showed that a substantial burden of health issues spanning multiple organ systems is experienced by patients who survive after the acute phase of COVID-19. The most frequent symptoms reported after acute infection were fatigue, muscle weakness, sleep disturbances, headache, dyspnoea, anxiety, depression, and anosmia. Two studies indicate that women are overrepresented amongst post-COVID-19 syndrome patients suffering from fatigue, headache, dyspnoea, or anosmia. However, the representativeness of the studies and the explicitness of provided information were insufficient due to lacking variables and/or small numbers of cases and the short duration of follow-up. Sex- and gender-specific predictors of post-COVID-19 syndrome are currently unknown.

Added value of this study: In a large cohort study (n=2799) with long follow-up (mean follow-up 197±77 days), we investigated sex- and gender-specific predictors of post-COVID-19 health sequelae. Our data allow for identification of sex- and gender-specific predictors of post-COVID-19 syndrome. In a multivariable association model, post-COVID-19 syndrome was associated with severity of illness and number of symptoms during acute SARS-CoV-2 infection in both sexes, while pre-existing mental illness and cardiovascular risk factors were significant predictors only in women. Conversely, obesity was independently associated with post-COVID-19 syndrome in men, but not in women. Gender-related risk factors of post-COVID syndrome were feminine traits and higher amount of domestic stress, both increasing

the odds of post-COVID-19 syndrome in women, while pregnancy during acute COVID-19 illness and responsibility for childcare protected women, and responsibility for household work protected men from experiencing post-COVID-19 syndrome.

Implications of all the available evidence: Evidence indicates that mortality from COVID-19 infection is higher in men than women. We provide evidence that female sex and gender is associated with long-term sequelae of COVID-19. Our data reinforce the importance of including gender to identify patients at risk for post-COVID-19 syndrome so that the functional return of both male and female COVID-19 survivors can be maximized.

Introduction

The coronavirus disease (COVID)-19 pandemic has become one of the greatest public health challenges in modern times. As the COVID-19 pandemic continues to evolve across the globe, male sex, cardiovascular and metabolic diseases, and advanced age have been identified as predominant risk factors for a more severe disease course of COVID-19 and poor prognosis.¹ Accordingly, male patients with COVID-19 are reported to die at twice the rate of females when they contract the virus.² Biological (sex) differences in immune responses and expression levels of receptors responsible for viral entry and priming have been suggested to account for the higher COVID-19-related mortality rates seen in men.^{3,4} Furthermore, male specific comorbidities such as cardiometabolic diseases may explain the greater susceptibility for COVID-19-related complications. However, despite the emerging understanding of sex differences in COVID-19, many questions including the impact of social and behavioural (gender) factors on COVID-19 remain.

Increasing evidence suggests that Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) can cause a prolonged disease course beyond acute illness.^{5,6} Only few studies to date have examined the clinical presentation of post-COVID-19 syndrome and report fluctuating and unpredictable symptoms which affect pulmonary and extrapulmonary organs thereby posing a rising burden on healthcare systems. Two large cohort studies suggest that women are overrepresented amongst patients suffering from neurological and psychological long-term consequences of COVID-19.^{7,8} However, sex- and gender-specific risk factors of post-COVID-19 syndrome are unknown.

Despite growing recognition of the relevance of sex and gender in the COVID-19 pandemic,⁹ the effect of gender, which comprises roles, norms, and behaviours that may vary by sex, has been inadequately examined and reported in current COVID-19 literature. The latter, however, is crucial to improve the effectiveness of health interventions, and to achieve gender and health equity goals. We therefore sought to investigate the factors associated with

post-COVID-19 syndrome in women and men by reporting gender roles and behaviours in addition to sex-disaggregated data in a large multi-centre cohort in Switzerland.

Methods

Study design and study population

This study is based on data from participants of the Swiss COGEN Cohort study, a prospective, observational cohort of polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infected individuals diagnosed between February and December 2020 at one of four Swiss study sites: the University Hospital Basel, the University Hospital Zurich, the University Hospital Bern, and the Cantonal Hospital Baden. Eligible patients were adults aged ≥ 18 years who survived acute COVID-19 infection and fluent in German, English, French, or Italian and able to provide informed consent. The study protocol was approved by the responsible ethics committee of the Canton of Basel (EKNZ, ethics approval #2020-01311). Informed consent was obtained from all participants or their legal representative, as appropriate. More details on study design and population are provided in **Supplementary Methods**.

Procedures and data sources

After a minimum follow-up time of 60 days (mean follow-up time 197 ± 77 days), each participant was contacted by telephone and was asked to complete a questionnaire either by phone, email or written form. Details regarding the questionnaire are provided in **Supplementary Methods**. Out of 5838 patients, 2858 patients or their legal representatives completed the questionnaire after giving informed consent. Out of 2858 patients, 52 patients (8 women and 44 men) died during or after treatment for COVID-19, 7 did not meet inclusion criteria. A flowchart depicting patient recruitment is provided in **Figure 1** and more details on procedures and data sources are given in **Supplementary Methods**.

Outcome measures

The primary outcome measure of our analysis was defined as the persistence of at least one COVID-19 related symptom for more than 60 days. Secondary outcome measures included the description of current quality of life as compared to before the COVID-19 disease (much better, slightly better, about the same, slightly worse or much worse compared to before COVID-19), hospital readmission (yes or no), and the nature (shortness of breath, reduced exercise capacity/physical weakness, chest pain, joint pain, skin changes, loss or change of smell, loss of sense or taste, visual disorders, excess salivation, concentration problems, loss of memory or forgetfulness, balance problems, depression, anxiety, persistent pain, sensory disturbances, palsy, trembling, headache and/or other symptoms) of persistent symptoms. Additionally, patients were asked in the questionnaire to elaborate on their experience in free text.

Statistical analyses

A detailed description of the statistical method is provided in **Supplementary Methods**. Briefly, descriptive statistics for baseline characteristics included means and standard deviations or counts and percentages of total for categorical variables. Participants were stratified by sex (binary). For group comparisons, exploratory p-values from t-tests for continuous variables, χ^2 test, or Fisher's exact tests for categorical variables were applied, as appropriate. The primary outcome of persistent symptoms at a minimum of 60 days following acute SARS-CoV-2 infection, was addressed with multiple logistic regression models (**Supplementary Methods**). The statistical analysis was performed through a fully scripted data management system to combine decrypted data from different sources, data pre-processing, and analysis pathway, using the statistical programming environment R for computations and visualization.¹⁰ Models were fitted to complete case (CC) populations first, in which all patients with missing data were excluded row-wise, and subsequently a sensitivity analysis with 100-fold multiply imputed (MI) data sets was performed.¹¹

Results

Patient baseline characteristics

The final study cohort comprised 2799 individuals of whom 1285 (45.9%) were women and 1514 (54.1%) were men (**Figure 1**). The mean age ($\pm$ SD) of the study population was 44 ± 17 years. The most common risk condition in the overall cohort was hypertension (431 patients, 15.4%), followed by obesity (402 patients, 14.4%). Cardiovascular disease including valvular heart disease, cardiomyopathies, or coronary artery disease, was present in 304 patients (10.9%). On average, men were older than women (45 ± 17 years vs 42 ± 16 years, $p<0.001$), had a higher BMI (26.2 ± 4.4 kg/m² vs 24.5 ± 5.2 kg/m², $p<0.001$), were more often smokers (29.6% vs 25.4%, $p=0.014$), more often had dyslipidaemia (9.1% vs 4.8%, $p<0.001$), diabetes mellitus (7.7% vs 2.9%, $p<0.001$), hypertension (19.0% vs 11.2%, $p<0.001$), and pre-existing cardiovascular disease (13.0% vs 8.3%, $p<0.001$), while women more often had a positive family history of coronary artery disease (15.6% vs 12.5%, $p=0.022$) and more often suffered from pre-existing autoimmune disorders (9.7% vs 5.3%, $p<0.001$). Baseline characteristics of the study population are summarized in **Table 1**. All sex- and gender-related baseline characteristics are provided in **Table 2** and described in **Supplementary Results**.

Acute COVID-19 illness

Out of 2799 individuals who were tested positive for SARS-CoV-2 and survived acute SARS-CoV-2 infection, 2336 (83.5%, 1131 [88.0%] women and 1205 [79.6%] men) remained outpatients, 463 (16.5%) were inpatients. 298 patients (10.6%, 106 women [8.2%] and 192 men [12.7%]) were admitted to a normal ward, and 165 (5.9%, 48 women [3.7%] and 117 men [7.7%]) were admitted to an intermediate or intensive care unit ($p<0.001$ for men vs women, **Table 1**). Amongst hospitalized patients, there was strong evidence for sex differences in routine laboratory markers of inflammation with the maximum C-reactive protein level being significantly higher in men (142.3 ± 110.64 µg/dL in men vs 103.98 ± 114.3 µg/dL in women, $p=0.001$, **Table 1**). There was no evidence for sex differences in maximal white blood cell counts (11.8 ± 15.1 G/L in women and 10.8 ± 6.5 G/L in men, $p=0.296$), and weak evidence for

lower minimal lymphocyte count in men, with minimal lymphocyte counts in men fulfilling the criteria for lymphopenia (0.9 ± 1.4 G/L in men vs 1.5 ± 4.7 G/L in women, $p=0.056$, **Table 1**). The average number of reported symptoms during acute COVID-19 was higher in women as compared to men (5.2 ± 2.4 in women vs 4.4 ± 2.3 in men, $p<0.001$). Accordingly, more women than men reported to have suffered from more than five symptoms during acute COVID-19 (44.7% in women vs 29.9% in men, $p<0.001$, **Table 1**).

Post-COVID-19 sequelae

During a mean follow-up time of 197 days 1024 (36.8%) individuals reported at least one persistent symptom (primary outcome measure). 152 (5.5%) individuals (66 [5.2%] women and 86 [5.7%] men, $p=0.573$ for women vs men, **Table 1**) were re-hospitalized at least once for persistent symptoms or complications of COVID-19. 807 patients (28.8%) reported a worse quality of life as compared to their pre-illness situation ($p=0.139$ for women vs men, **Table 1**). Women more often reported at least one persistent symptom as compared to men (43.0% vs 31.5%, $p<0.001$, **Table 1, Figure 2**) and the average number of reported symptoms at follow-up was significantly higher in women as compared to men (1.31 ± 2.2 vs 0.92 ± 1.8 , $p<0.001$, **Table 1**). Across all organ-systems, except for cardiovascular and gastrointestinal symptoms, women more often reported persistent symptoms as compared to men (**Figure 2**). Amongst individuals with persistent symptoms, the most frequent symptom reported at follow-up was reduced exercise tolerance and reduced resilience, which was reported by 43% of men and 41% of women with persistent symptoms (**Figure 3**). More details on specific post-COVID-19 symptoms and subgroup analyses are provided in **Supplementary Results**.

Sex- and gender-specific determinants of post-COVID-19 syndrome

Individuals who reported at least one persistent symptom at follow-up were more likely to be female (odds ratio [OR] and 95% confidence interval [CI] $1.65[1.26-2.17]$, $p=0.0003$) or obese ($1.40[1.08-1.81]$, $p=0.01$), suffered more often from >5 symptoms during acute COVID-19 illness ($2.69[2.25-3.21]$, $p<0.001$), were more often hospitalized on the normal ward

(1.65[1.21-2.25], $p=0.002$) or ICU (4.00[2.66-6.02], $p<0.0001$), had more often pre-existing mental illness (1.63[1.08-2.48], $p=0.021$), and reported more often an increased domestic stress-level (1.10[1.05-1.14], $p<0.0001$, **Table 3**). Being the main person responsible for childcare/care of family members was associated with a reduced risk of experiencing post-COVID-19 syndrome (0.95[0.91-0.99], $p=0.014$, **Table 3**).

In women, having experienced more than 5 symptoms (2.43[1.89-3.13], $p<0.0001$) or being hospitalized at the ICU during acute COVID-19 illness (3.63[1.66-7.93], $p=0.001$) as well as the presence of cardiovascular risk factors (1.39[1.03-1.89], $p=0.033$), pre-existing mental illness (1.81[1.00-3.26], $p=0.049$), an increased domestic stress level (1.15[1.08-1.22], $p<0.0001$), self-assessment of gender identity according to BEM score (1.12[1.02-1.24], $p=0.02$) were all associated with an increased risk of experiencing post-COVID-19 syndrome (**Table 4, Figure 4**). Conversely, being the main person responsible for childcare/care of family members was associated with lower odds of post-COVID-19 syndrome (0.90[0.84-0.96], $p=0.002$, **Table 4, Figure 4**). Similarly, there was a trend towards an inverse relationship between being pregnant at the time of acute COVID-19 illness and the occurrence of post-COVID-19 syndrome (0.48[0.23-1.01], $p=0.054$, **Table 4, Figure 4**).

In men, obesity (1.44[1.03-2.02], $p=0.034$), having experienced more than 5 symptoms during acute COVID-19 illness (2.95[2.25-3.83], $p<0.0001$), being hospitalized at normal ward (1.77[1.18-2.66], $p=0.006$) or ICU (4.39[2.68-7.19], $p<0.0001$) during acute COVID-19 illness were all associated with an increased risk of post-COVID-19 syndrome (**Table 5, Figure 4**). The presence of pre-existing cardiovascular disease was only weakly associated with increased odds of post-COVID-19 syndrome (1.45[0.98-2.15], $p=0.066$, **Table 5, Figure 4**). Conversely, being the main person responsible for household work was associated with a reduced risk of experiencing post-COVID-19 syndrome in men (0.82[0.69-0.97], $p=0.021$, **Table 5, Figure 4**).

Discussion

Although growing attention is paid to the relevance of sex and gender in the COVID-19 pandemic, the influence of both variables on the occurrence of post-COVID-19 symptoms is currently unknown. Our study is the first to examine the combined effect of clinical biological variables and variables that refer to the sociocultural dimension gender on COVID-19 health consequences. While our study confirms previous data pointing to a higher prevalence of post-COVID-19 syndrome in women, to our knowledge, we are the first to identify sex-and gender-specific risk factors for post-COVID-19 multiorgan dysfunction. In our cohort of individuals with proven SARS-CoV-2 infection who were on average followed up for as long as 6.5 months after acute illness, 43% of women and 32% of men reported at least one persistent symptom months after acute illness with the number of symptoms per individual being also significantly higher in women. Pre-existing mental illness and cardiovascular risk factors increased the odds of post-COVID-19 syndrome in women, but not in men. Conversely, obesity was an independent predictor of post-COVID-19 syndrome in men, but not in women. Gender-related variables were independently associated with post-COVID-19 syndrome with self-assessed gender identity and a higher domestic stress level both increasing the odds of post-COVID-19 syndrome in women. In contrast, pregnancy during acute COVID-19 illness and responsibility for childcare seemed to protect women from experiencing post-COVID-19 syndrome. Our data indicate that post-COVID-19 sequelae and their predictors differ between men and women suggesting that a tailored and sex- and gender-sensitive approach of healthcare services may be required to support their needs.

Consistent with our observation, previous studies report that one to two thirds of patients did not return to baseline health within six months following acute SARS-CoV-2 infection.^{12,13} Not surprisingly, persistent symptoms were associated with worsened quality of life which has previously been reported to occur in one third of cases of mild COVID-19 cases and is consistent with our data.¹² Of note, however, the incidence rates of post-COVID-19 syndrome vary widely in previous studies ranging from 10% to 96% of patients reporting

persistent symptoms following acute illness.¹⁴⁻¹⁶ Differences in study populations, follow-up periods, and sample sizes likely affect the comparison of results across studies. Also, many previous reports have several limitations, including lack of an agreed-upon case definition and potential bias, as most reports excluded either outpatients or hospitalized patients. Re-hospitalisation due to persistent symptoms or complication of COVID-19 has been reported to occur in 9% to 20% of patients.^{17,18} The observed readmission rate of 5.5% in our study is lower than these estimates. Although we did not analyse the most common reasons for readmission, the lower re-hospitalization rate in our study likely reflects the lower acuity of illness in our cohort relating to differences in age and disease severity between study populations. Further research is needed to assess the extent to which improvements in the management of post-COVID-19 syndrome might reduce readmission rates.

In our study, reduced exercise tolerance and/or resilience was the most commonly reported symptom occurring in 41% of women and 43% of men with post-COVID-19 syndrome. While differences in study populations and outcome measurement are likely to affect the comparability of studies on post-COVID-19 syndrome, a relatively high prevalence of chronic fatigue, dyspnoea or exercise intolerance, and psychological symptoms have consistently been noted across studies.^{19,20} In particular, neuropsychiatric symptoms including depression and anxiety, cognitive impairment, headache or olfactory dysfunction seem to persist in a substantial number of patients (32% of individuals in our study) which is in accordance with previous studies.^{15,16} The incidence of persistent neuropsychiatric symptoms was significantly higher in women as compared to men in our study indicating that women exhibit a higher vulnerability to encountering long-term neurological and mental health consequences of COVID-19. The latter is supported by the fact that women reported a higher post-COVID-19 stress level as compared to men which is consistent with data from the SARS epidemic in 2003 demonstrating that female SARS survivors encountered higher stress levels and higher levels of depression and anxiety.²¹ As an involvement of angiotensin-converting enzyme (ACE) receptors has been suggested to be a gateway for this neurotropism,²² the known sex-specific expression levels of these receptors⁴ might be a potential mechanism

driving the observed gender dysbalance in long-term neuropsychiatric consequences of SARS-CoV-2. Finally, intracerebral microembolisation has recently been described in patients with a severe disease course of COVID-19 and might play a role in neuropsychiatric long-term effects of the disease.²³ The fact that men in our study were more often on antithrombotic or anticoagulant treatment as compared to women could have exerted a protective effect on the endothelium of brain capillaries and might have prevented long-term sequelae. Independent of the underlying mechanism, the high incidence of persistent neuropsychiatric symptoms in women calls for implementation of targeted treatments for individuals affected by post-COVID-19 syndrome.

In our statistical model, we noted an association between pre-existing diagnosis of mental illness and the incidence of post-COVID-19 syndrome in women, but not in men. While an association between known depression and chronic postviral fatigue has previously been described,²⁴ our study is the first to observe that pre-existing mental disorders increases the risk of post-COVID-19 syndrome in women, but not in men. This sex-specific association might be due to the higher prevalence of mental illness in the female population which is also seen in our cohort. Also, a specific immune signature has previously been suggested to account for the persistence of fatigue following acute illness,²⁵ and preliminary data indicate that dysfunctional immune cells with an autoimmune phenotype are present in patients with post-COVID-19 syndrome, particularly in those with persistent neurological symptoms.²⁶ Thus, the higher prevalence of autoimmune disorders in our female study population as well as known sex-differences in immune responses to SARS-CoV-2³ including a more robust T-cell response and a potential long-term hyperinflammatory state in women following SARS-CoV-2 infection²⁷ might drive sex differences in the prevalence of post-COVID-19 syndrome. Also, the presence of lymphopenia in men being hospitalized for acute COVID-19 in our study supports this assumption as the latter might be associated with a lower number of autoreactive B- and T-cell lymphocytes. Accordingly, a recent study comparing 50 individuals suffering from post-COVID-19 syndrome to 50 SARS-CoV-2 negative controls found a higher prevalence of autoimmune disorders and elevated ANA titers in the post-COVID-19 cohort.¹⁹ Therefore, we

propose to study this interaction in prospective well-powered studies, even though no consistent association between a persistent (auto)immune response to the virus and post-COVID-19 syndrome has been reported across multiple smaller studies.²⁵ Furthermore, as a multifactorial aetiology of post-COVID-19 syndrome seems likely, our study emphasizes the importance of identifying clusters of sex-specific risk markers driving post-COVID syndrome in women and men so that multidisciplinary care can be offered to post-COVID patients.

Women in our study reported a higher domestic stress level as compared to men. Accordingly, an increased stress level at home was a significant predictor of post-COVID-19 syndrome in women, but not in men. This is consistent with recent work demonstrating an association between lacking social support, female sex and COVID-19-related posttraumatic stress disorder¹⁵ indicating that women suffer more emotional reactivity and stress response symptoms. Although no data exist regarding the impact of domestic emotional stress on viral disease outcomes, our data are also in line with previous cardiovascular studies demonstrating that family and marital stress is a strong and independent risk factor for the progression of atherosclerosis in women, while relative protection from the disease was obtained from partner support.²⁸ Consequently, our study emphasizes the importance of psychosocial interventions with an emphasis on coping with family-related stress exposure in women affected by post-COVID-19 syndrome.²⁹ The fact that household responsibility (in men), responsibility for childcare (in women), and pregnancy at the time of acute SARS-CoV-2 infection all had protective effects on post-COVID-19 syndrome may indicate that taking care of other individuals may either allow less time for self-reflection or provide a base for more positive thinking and optimistic attitude during recovery from COVID-19. These findings suggest that reduced social contact and loneliness might exacerbate symptoms of post-COVID syndrome. Finally, it is worth mentioning that being a single parent was associated with a trend towards higher odds of post-COVID-19 syndrome in the overall association model. Given that being a single parent in Switzerland usually comprises childcare responsibilities as well as full-time employment, it is conceivable that

employment level and the resulting exposure to a higher level of stress also plays a role in post-COVID-19 risk prediction.

Our study has several limitations related to its cross-sectional and observational study design. First, like all observational studies, residual confounding due to unmeasured variables in our dataset is possible. However, the risk factors in our study covered many aspects of demographic characteristics, pre-existing diseases, sex-and gender-specific variables, and acute COVID-19 simultaneously. Second, increasing awareness of post-COVID-19 syndrome during the last few months may have resulted in more frequent reporting of health issues by participants over the course of the study. Third, compared to individuals not participating in our study, participants in our study were more often hospitalized during acute COVID-19, which could increase our estimate of the prevalence of post-COVID-10 syndrome. Conversely, post-COVID-19 syndrome prevalence may have been underestimated if individuals with prolonged and severe symptoms or cognitive dysfunction were more likely not to complete the questionnaire. Fourth, the effect that more men than women died during acute infection may have shifted the appearance of post-COVID-19 syndrome towards the female demographic group. However, the number of cases contributing to this phenomenon are small and likely did not cause a statistically significant effect. Finally, self-selection or other biases may have occurred if individuals who are more concerned with their health were more likely to participate.

Taken together, our multicentre study is the first to our knowledge to demonstrate that characteristics and risk factors of post-COVID-19 syndrome differ between men and women. While 37% of individuals in the current study showed symptoms consistent with post-COVID-19 syndrome after a mean follow-up time of 197 days, our results demonstrate that women in our cohort were at particular high risk of developing post-COVID-19 syndrome. Our data indicate that both biological variables as well as gender identity and social roles were independent predictors of post-COVID-19 syndrome. We emphasize that multidisciplinary and sex- and gender-tailored therapeutic strategies are of particular importance in post-COVID-19 syndrome given that women receive less often intensive diagnostic and treatment

interventions as compared to men.³⁰ Sex- and gender-specific research on the underlying pathophysiology of post-COVID-19 syndrome is now urgent to better understand symptom development and identify targets for intervention.

Data Availability

Data sharing

Based on the Business Administration System for Ethics Committees (BASEC) ethics approval, the non-anonymized raw data cannot be shared publicly. However, anonymised data that underlie the results reported in this article will become available to interested parties for non-commercial reasons, after the publication upon reasonable requests made to the corresponding author. Data requestors will need to sign a data access agreement.

Dissemination to participants and related patient and public communities

The size of the study population precludes direct dissemination to participants.

Declarations

Research ethics approval

The study was approved by the responsible ethics committee of the Canton of Basel, Switzerland (EKNZ; BASEC-Nr 2020-01311). Informed consent was obtained from all participants or their legal representative, as appropriate.

Competing interests

CG has received research grants from the Novartis Foundation and speaker's fees from Sanofi Genzyme, Switzerland outside of the submitted work. The University Hospital Zurich (CG, RRB, APP, MM, PAK) holds a research contract with GE Healthcare outside of the submitted work. CG and AM have received research grants from Bayer Pharmaceuticals outside of the submitted work. JCS and TS reports (full departmental disclosure) grants from Orion Pharma, Abbott Nutrition International, B. Braun Medical AG, CSEM AG, Edwards Lifesciences

Services GmbH, Kenta Biotech Ltd, Maquet Critical Care AB, Omnicare Clinical Research AG, Nestle, Pierre Fabre Pharma AG, Pfizer, Bard Medica S.A., Abbott AG, Anandic Medical Systems, Pan Gas AG Healthcare, Bracco, Hamilton Medical AG, Fresenius Kabi, Getinge Group Maquet AG, Dräger AG, Teleflex Medical GmbH, Glaxo Smith Kline, Merck Sharp and Dohme AG, Eli Lilly and Company, Baxter, Astellas, Astra Zeneca, CSL Behring, Novartis, Covidien, Nycomed, and Phagesis, outside of the submitted work. The money went into departmental funds, no personal financial gain applies. All other authors declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

Funding

This project is funded by the Swiss National Science Foundation (Project #196140, to CG, CEG, and VRZ), the LOOP Zurich (CG, VRZ, UH) and an unrestricted research grant from the intensive care unit (ICU) research foundation of the University Hospital of Basel (CEG). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to the anonymized data in the study and share final responsibility for the decision to submit for publication.

Authors' contributions

CG, CEG, and VRZ conceptualized and designed the Swiss COGEN study. CEG, CS, SB, KPB, NH coordinated the study. CEG, PO, SB, AM, NZ prepared the study data. UH, MD, and CEG, SB, and CG have verified the underlying data, performed the statistical analysis and prepared tables and figures. CG, CEG, CS, UH, MD, and NL wrote the first manuscript draft. VRZ, VT, PAK, RRB, MM, APP, RS, AZ, JHB, AF, MS, HP, JCS, RT, GMK, JB, and STS contributed to interpretation of the results and critical revision of the manuscript. SB, KPB, CEG, CG, SDB, CA, DP, and BW implemented and coordinated the recruitment of study participants and biobank samples. TS, JCS, ADC, CH, MP, DFS, LM, MCG, ASZ, LC, DJS, AH, MG, NM, AR, FF, AT, JB, and AP contributed to the enrolment of study participants and

data collection. All authors approved the final manuscript. CG is the guarantor for the study. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Acknowledgement

We would like to thank the study administration staff including Elvira Krämer, Livia Krüger, Mariano Paredes Heck, Mina Qadirie, Marie-Louise Sieber, Anna Zaiser, and Anja Zabel as well as the staff of the Department of Nuclear Medicine of the University Hospital Zurich and the Intensive Care Units of the University Hospital Basel and the University Hospital Zurich for their excellent work and dedication to this study. And last, we thank all the study participants for their valuable time and commitment to the Swiss COGEN Cohort.

Figure Legend

Figure 1: Flowchart depicting patient selection. IMC, intermediate care unit; ICU, intensive care unit.

Figure 2: Persistent symptoms reported at follow-up stratified by sex. Symptoms are clustered in organ-systems and shown as percentage of total study population (n=2799). Red. exerc. tol, reduced exercise tolerance.

Figure 3: Persistent symptoms reported at follow-up stratified by sex and symptom. Data are presented as percentage of patients reporting persistent symptoms (n=1024).

Figure 4: Forest Plot depicting odds ratios and 95% confidence intervals of risk/protective factors associated with post-COVID-19 syndrome in women and men. ICU, intensive care unit; IMC, intermediate care unit; CVRF, cardiovascular risk factor.

References

1. Ma Q, Hao ZW, Wang YF. The effect of estrogen in coronavirus disease 2019 (COVID-19). *Am J Physiol Lung Cell Mol Physiol* 2021.
2. Islam N, Shkolnikov VM, Acosta RJ, et al. Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries. *Bmj* 2021; **373**: n1137.
3. Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature* 2020; **588**(7837): 315-20.
4. Muus C, Luecken MD, Eraslan G, et al. Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. *Nat Med* 2021; **27**(3): 546-59.
5. Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. *Jama* 2020; **324**(22): 2251-2.
6. NICE. COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020. <https://www.nice.org.uk/guidance/ng188/chapter/4-Planning-care> (accessed 27.05.2021 2021).
7. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med* 2021; **27**(4): 626-31.
8. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet* 2021; **397**(10270): 220-32.
9. Tadiri CP, Gisinger T, Kautzy-Willer A, et al. The influence of sex and gender domains on COVID-19 cases and mortality. *Cmaj* 2020; **192**(36): E1041-e5.
10. R: A language and environment for statistical computing. 2021-05-18 2021. <https://www.r-project.org/> (accessed 2021-06-19 2021).
11. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Statistics in Medicine* 2011; **30**(4): 377-99.
12. Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. *JAMA Network Open* 2021; **4**(2): e210830-e.
13. Carvalho-Schneider C, Laurent E, Lemaignan A, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. *Clin Microbiol Infect* 2021; **27**(2): 258-63.
14. Carfi A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. *Jama* 2020; **324**(6): 603-5.
15. Cai X, Hu X, Ekumi IO, et al. Psychological Distress and Its Correlates Among COVID-19 Survivors During Early Convalescence Across Age Groups. *Am J Geriatr Psychiatry* 2020; **28**(10): 1030-9.
16. Lechien JR, Chiesa-Estomba CM, Beckers E, et al. Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. *J Intern Med* 2021.

17. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes Among Patients Hospitalized With COVID-19. *Ann Intern Med* 2021; **174**(4): 576-8.
18. Lavery AM, Preston LE, Ko JY, et al. Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission - United States, March-August 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**(45): 1695-9.
19. Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". *Ann Clin Transl Neurol* 2021; **8**(5): 1073-85.
20. Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. *PloS one* 2020; **15**(11): e0240784.
21. Lee AM, Wong JG, McAlonan GM, et al. Stress and psychological distress among SARS survivors 1 year after the outbreak. *Can J Psychiatry* 2007; **52**(4): 233-40.
22. Guedj E, Campion JY, Dudouet P, et al. (18)F-FDG brain PET hypometabolism in patients with long COVID. *Eur J Nucl Med Mol Imaging* 2021: 1-11.
23. Nauen DW, Hooper JE, Stewart CM, Solomon IH. Assessing Brain Capillaries in Coronavirus Disease 2019. *JAMA Neurol* 2021; **78**(6): 760-2.
24. Cope H, Mann A, David A, Pelosi A. Predictors of chronic "postviral" fatigue. *The Lancet* 1994; **344**(8926): 864-8.
25. Natelson BH, Haghighi MH, Ponzio NM. Evidence for the Presence of Immune Dysfunction in Chronic Fatigue Syndrome. *Clinical and Vaccine Immunology* 2002; **9**(4): 747-52.
26. Song E, Bartley CM, Chow RD, et al. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. *Cell Rep Med* 2021; **2**(5): 100288.
27. Zhao YM, Shang YM, Song WB, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. *EClinicalMedicine* 2020; **25**: 100463.
28. Orth-Gomér K, Schneiderman N, Wang HX, Walldin C, Blom M, Jernberg T. Stress reduction prolongs life in women with coronary disease: the Stockholm Women's Intervention Trial for Coronary Heart Disease (SWITCHD). *Circ Cardiovasc Qual Outcomes* 2009; **2**(1): 25-32.
29. Wang HX, Leineweber C, Kirkeeide R, et al. Psychosocial stress and atherosclerosis: family and work stress accelerate progression of coronary disease in women. The Stockholm Female Coronary Angiography Study. *J Intern Med* 2007; **261**(3): 245-54.
30. Vogel B, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. *Lancet* 2021; **397**(10292): 2385-438.

Patient characteristics	Overall (n=2799)	Women (n=1285)	Men (n=1514)	p-value (men vs women)
Age, years, mean(SD)	43.59 (16.54)	42.19 (16.21)	44.78 (16.73)	<0.001
BMI, kg/m ² , mean(SD)	25.41 (4.86)	24.46 (5.20)	26.23 (4.40)	<0.001
Follow-up time, days, mean(SD)	197.37 (76.99)	199.86 (76.88)	195.26 (77.04)	0.115
Cardiovascular risk factors				
Hypertension, n(%)	431 (15.4)	144 (11.2)	287 (19.0)	<0.001
Dyslipidemia, n(%)	200 (7.1)	62 (4.8)	138 (9.1)	<0.001
Diabetes mellitus, n(%)	153 (5.5)	37 (2.9)	116 (7.7)	<0.001
Family history of CAD, n(%)	388 (13.9)	200 (15.6)	188 (12.5)	0.022
Smoking, n(%)	772 (27.7)	325 (25.4)	447 (29.6)	0.014
Obesity (BMI > 30kg/m ²), n(%)	402 (14.4)	159 (12.4)	243 (16.1)	0.007
Pre-existing comorbidities				
Mental disorder, n(%)	140 (5.0)	75 (5.8)	65 (4.3)	0.075
Autoimmune/rheumatoid diseases, n(%)	205 (7.3)	125 (9.7)	80 (5.3)	<0.001
Neurological disease, n(%)	129 (4.6)	59 (4.6)	70 (4.6)	1
Cardiovascular disease, n(%)	304 (10.9)	107 (8.3)	197 (13.0)	<0.001
Pulmonary disease, n(%)	199 (7.1)	102 (7.9)	97 (6.4)	0.134
Cancer, n(%)	143 (5.1)	65 (5.1)	78 (5.2)	0.989
Medications				
None, n(%)	1653 (59.1)	737 (57.4)	916 (60.5)	0.099
Analgetics, n(%)	276 (9.9)	157 (12.2)	119 (7.9)	<0.001
Cardiovascular drugs including aldosterone antagonists, n(%)	437 (15.6)	136 (10.6)	301 (19.9)	<0.001
Lipid lowering drugs, n(%)	181 (6.5)	45 (3.5)	136 (9.0)	<0.001
Antidiabetics, n(%)	138 (4.9)	34 (2.6)	104 (6.9)	<0.001
Anticoagulant/antithrombotic medication, n(%)	138 (4.9)	35 (2.7)	103 (6.8)	<0.001
Asthma treatments, n(%)	106 (3.8)	54 (4.2)	52 (3.4)	0.337
Immunosuppressive medication, n(%)	51 (1.8)	23 (1.8)	28 (1.8)	1
Acute COVID-19 disease characteristics				
Disease severity				<0.001
Outpatient	2336 (83.5)	1131 (88.0)	1205 (79.6)	
Normal ward hospitalization	298 (10.6)	106 (8.2)	192 (12.7)	
Intermediate or intensive care unit hospitalization	165 (5.9)	48 (3.7)	117 (7.7)	
Average number of symptoms during acute COVID-19 illness, mean(SD)	4.77 (2.37)	5.23 (2.41)	4.39 (2.27)	<0.001
Acute COVID-19 symptoms >5, n(%)	1028 (36.7)	575 (44.7)	453 (29.9)	<0.001
Highest white blood cell count, G/L, mean(SD) *	11.10 (10.19)	11.81 (15.11)	10.75 (6.50)	0.296
Lowest lymphocyte count, G/L mean(SD) *	1.07 (2.93)	1.46 (4.70)	0.89 (1.41)	0.056
CRP, µg/dL, mean(SD) *	129.65 (113.16)	103.98 (114.26)	142.27 (110.64)	0.001
Post-COVID-19 sequelae				
Hospital readmission, n(%)	152 (5.5)	66 (5.2)	86 (5.7)	0.573
Persistent symptoms (≥1), n(%)	1024 (36.8)	550 (43.0)	474 (31.5)	<0.001
Average number of post-COVID symptoms, mean(SD)	1.10 (2.04)	1.31 (2.2)	0.92 (1.8)	<0.001
QoL				0.139
Similar QoL than before COVID-19, n(%)	1697 (61.4)	764 (60.1)	933 (62.4)	
Much better QoL than before COVID-19, n(%)	111 (4.0)	46 (3.6)	65 (4.3)	
Much worse QoL than before COVID-19, n(%)	128 (4.6)	64 (5.0)	64 (4.3)	
Slightly better QoL than before COVID-19, n(%)	151 (5.5)	62 (4.9)	89 (6.0)	
Slightly worse QoL than before COVID-19, n(%)	679 (24.5)	335 (26.4)	344 (23.0)	

Table 1: Baseline characteristics of the **total study population** stratified by sex. BMI, body mass index; CRP, C-reactive protein; QoL, quality of life. * hospitalized patients only, p-values are reported for comparison between women and men.

Socioeconomic (Gender) variables	Overall (n=2799)	Women (n=1285)	Men (n=1514)	p-value (men vs women)
Education:				0.116
University or technical college degree, n(%)	1333 (47.9)	595 (46.4)	738 (49.1)	
Secondary education or vocational degree, n(%)	1094 (39.3)	508 (39.6)	586 (39.0)	
Primary education, n(%)	191 (6.9)	103 (8.0)	88 (5.9)	
No educational qualification, n(%)	166 (6.0)	76 (5.9)	90 (6.0)	
Marital status				0.001
Divorced/separated	185 (6.6)	104 (8.1)	81 (5.4)	
Married/partnership	1299 (46.7)	560 (43.7)	739 (49.3)	
Single	1231 (44.2)	578 (45.1)	653 (43.5)	
Widowed	67 (2.4)	40 (3.1)	27 (1.8)	
Single parent, n(%)	220 (7.9)	133 (10.4)	87 (5.8)	<0.001
Lives alone, n(%)	898 (32.3)	431 (33.6)	467 (31.1)	0.175
Income				<0.001
Earns highest income in household, n(%)	1547 (55.8)	523 (40.8)	1024 (68.7)	
Equally between partners, n(%)	430 (15.5)	208 (16.2)	222 (14.9)	
Earns lowest income in household, n(%)	795 (28.7)	550 (42.9)	245 (16.4)	
Main person responsible for household work, n(%)				<0.001
No, n(%)	662 (23.9)	166 (13.0)	496 (33.2)	
Equal distribution between partners, n(%)	931 (33.6)	393 (30.7)	538 (36.0)	
Yes, n(%)	1181 (42.6)	720 (56.3)	461 (30.8)	
Average domestic stress level (scale 1-10, 10=maximum), mean±SD	3.35 (2.18)	3.72 (2.34)	3.04 (1.99)	<0.001
Main responsibility for childcare/care of family members (min 1-max 6), mean±SD	1.80 (2.19)	1.94 (2.28)	1.68 (2.11)	0.002
Femininity as assessed by BEM scale (scale 1-7, 7=maximum), mean±SD	3.06 (0.92)	3.13 (0.93)	3.00 (0.92)	0.001
Self-assessment of gender identity (scale 1-7, 7=only feminine traits, 1=only masculine traits), mean±SD	3.79 (2.10)	5.49 (1.33)	2.35 (1.46)	<0.001
Female sex-specific characteristics				
Menopause, n(%)	-	381 (30.1)	-	
Postmenopausal hormone replacement, n(%)	-	28 (2.2)		
Pregnancy at the time of acute COVID-19 infection, n(%)	-	45 (3.6)	-	
Number of pregnancies during lifetime				
0		583 (47.0)		
1		186 (15.0)		
2		257 (20.7)		
3		135 (10.9)		
4		46 (3.7)		
≥5		34 (2.7)		
Pregnancy complications, n(%)		275 (21.4)		
Male sex-specific characteristics				
Regular testosterone administration, n(%)			21 (1.4)	

Table 2: Socioeconomic and sex-specific characteristics of men and women. p-values are reported for comparison between women and men.

General Association Model for post-COVID Syndrome in Overall Study Population (n=2599)			
Predictor Variables	OR	95% CI Confidence Interval	p-value
Age (years)	1.00	1.00-1.01	0.16
Obesity (BMI ≥ 30 kg/m ²)	1.40	1.08-1.81	0.01
Female sex	1.65	1.26-2.17	0.0003
Characteristics of acute COVID-19 illness			
> 5 symptoms during acute COVID-19 illness	2.69	2.25-3.21	<0.0001
Normal ward hospitalization for acute COVID-19 (reference: no hospitalization)	1.65	1.21-2.25	0.002
IMC or ICU hospitalization for acute COVID-19 (reference: no hospitalization)	4.00	2.66-6.02	<0.0001
Pre-existing risk factors and comorbidities			
Presence of CVRFs	1.20	0.97-1.48	0.085
Known autoimmune or rheumatoid disease	0.99	0.70-1.39	0.94
Known cardiovascular disease	1.22	0.90-1.64	0.20
Known cancer	1.00	0.67-1.50	1.00
Known respiratory disease	1.30	0.94-1.81	0.12
Known mental illness	1.63	1.08-2.48	0.021
Smoking	1.15	0.95-1.40	0.15
Socioeconomic (Gender) variables			
Single parent	1.35	0.96-1.88	0.081
Higher education	0.98	0.88-1.10	0.76
Earning lowest income in household	0.97	0.87-1.09	0.62
Being main person responsible for household work	0.92	0.81-1.04	0.17
Increased domestic stress level	1.10	1.05-1.14	<0.0001
Femininity as assessed by BEM scale	1.02	0.93-1.13	0.64
Self-assessment of gender identity	1.02	0.96-1.09	0.44
Being main person responsible for childcare/care of family members	0.95	0.91-0.99	0.014

Table 3: General model for the association between demographic characteristics, acute COVID-19 illness, preexisting disease, sex- and gender-specific variables and the occurrence of post-COVID syndrome in the overall study population. BMI: Body mass index; CVRFs, cardiovascular risk factors.

General Association Model for post-COVID Syndrome in Women (n=1188)			
Predictor Variables	OR	95% CI Confidence Interval	p-value
Age (years)	1.00	0.99-1.01	0.84
Obesity (BMI ≥ 30 kg/m ²)	1.36	0.90-2.06	0.14
Characteristics of acute COVID-19 illness			
> 5 symptoms during acute COVID-19 illness	2.43	1.89-3.13	<0.0001
Normal ward hospitalization for acute COVID-19 (reference: no hospitalization)	1.53	0.92-2.57	0.1
IMC or ICU hospitalization for acute COVID-19 (reference: no hospitalization)	3.63	1.66-7.93	0.001
Pre-existing risk factors and comorbidities			
Presence of CVRFs	1.39	1.03-1.89	0.033
Known autoimmune or rheumatoid disease	0.99	0.64-1.53	0.96
Known cardiovascular disease	0.82	0.50-1.33	0.41
Known cancer	0.89	0.49-1.61	0.70
Known respiratory disease	1.29	0.82-2.04	0.27
Known mental illness	1.81	1.00-3.26	0.049
Smoking	1.17	0.88-1.56	0.28
Female sex-specific variables			
Pregnancy at the time of acute COVID-19 illness	0.48	0.23-1.01	0.054
Menopause	1.00	0.66-1.50	0.99
Postmenopausal HRT	1.10	0.47-2.59	0.82
Socioeconomic (Gender) variables			
Single parent	1.41	0.90-2.20	0.13
Higher education	0.90	0.76-1.07	0.24
Earning lowest income in household	1.03	0.88-1.20	0.75
Being main person responsible for household work	1.13	0.93-1.37	0.22
Increased domestic stress level	1.15	1.08-1.22	<0.0001
Femininity as assessed by BEM scale	0.97	0.85-1.12	0.72
Self-assessment of gender identity	1.12	1.02-1.24	0.02
Being main person responsible for childcare/care of family members	0.90	0.84-0.96	0.002

Table 4: General model for the association between demographic characteristics, acute COVID-19 illness, preexisting disease, sex- and gender-specific variables and the occurrence of post-COVID syndrome in women. BMI: Body mass index; CVRFs, cardiovascular risk factors; HRT, hormone replacement therapy.

General Association Model for post-COVID Syndrome in Men (n=1377)			
Predictor Variables	OR	95% CI Confidence Interval	p-value
Age (years)	1.00	0.99-1.01	0.48
Obesity (BMI ≥ 30 kg/m ²)	1.44	1.03-2.02	0.034
Characteristics of acute COVID-19 illness			
> 5 symptoms during acute COVID-19 illness	2.95	2.26-3.83	<0.0001
Normal ward hospitalization for acute COVID-19 (reference: no hospitalization)	1.77	1.18-2.66	0.006
IMC or ICU hospitalization for acute COVID-19 (reference: no hospitalization)	4.39	2.68-7.19	<0.0001
Pre-existing risk factors and comorbidities			
Presence of CVRFs	1.02	0.76-1.38	0.89
Known autoimmune or rheumatoid disease	1.09	0.62-1.94	0.76
Known cardiovascular disease	1.45	0.98-2.15	0.066
Known cancer	1.11	0.63-1.94	0.72
Known respiratory disease	1.35	0.82-2.21	0.24
Known mental illness	1.36	0.72-2.57	0.35
Smoking	1.10	0.84-1.45	0.48
Male sex-specific variables			
Regular testosterone administration	2.18	0.81-5.89	0.12
Socioeconomic (Gender) variables			
Single parent	1.33	0.77-2.32	0.31
Higher education	1.04	0.88-1.22	0.67
Earning lowest income in household	0.99	0.83-1.18	0.89
Being main person responsible for household work	0.82	0.69-0.97	0.021
Increased domestic stress level	1.04	0.89-1.12	0.22
Femininity as assessed by BEM scale	1.08	0.94-1.24	0.25
Self-assessment of gender identity	0.97	0.89-1.06	0.56
Being main person responsible for childcare/care of family members	0.99	0.93-1.06	0.74

Table 5: General models for the association between demographic characteristics, acute COVID-19 illness, preexisting disease, sex- and gender-specific variables and the occurrence of post-COVID syndrome in men. BMI: Body mass index; CVRFs, cardiovascular risk factors.